middle.news
How Will PYC-003’s Final Dose Escalation Impact Polycystic Kidney Disease Treatment?
9:08am on Friday 8th of August, 2025 AEST
•
Biotechnology
Read Story
How Will PYC-003’s Final Dose Escalation Impact Polycystic Kidney Disease Treatment?
9:08am on Friday 8th of August, 2025 AEST
Key Points
Escalation to fourth and final dose cohort in Phase 1a Single Ascending Dose study
Safety Review Committee approval following review of initial dosing cohorts
Commencement of dosing in Polycystic Kidney Disease patients in Phase 1b
On track for repeat dose studies in PKD patients in Q4 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Pyc Therapeutics (ASX:PYC)
OPEN ARTICLE